Navigation Links
New patient satisfaction study with budesonide/formoterol combination therapy
Date:5/20/2008

Wilmington, DE May 20, 2008 A new open-label study evaluated patient satisfaction with budesonide/formoterol combination therapy and fluticasone/salmeterol combination therapy, as measured by the Asthma Treatment Satisfaction Measure (ATSM).1 Patients participating in the study were ages 18 years and older with moderate to severe asthma and had been previously treated with inhaled corticosteroids.1 Results were presented today at the International Conference of the American Thoracic Society held in Toronto, May 16-21, 2008.

Results showed that patients receiving budesonide/formoterol combination therapy administered as adjustable dosage reported significantly greater satisfaction on the ATSM overall (p=0.02) than patients receiving fluticasone/salmeterol combination therapy, especially in the categories of feel medication begins to work (p<0.001), dosing management (p<0.001), and timely relief of symptoms (p=0.037).1 Patients receiving budesonide/formoterol combination therapy fixed dose reported significantly greater satisfaction for timely relief of symptoms (p=0.002) and feeling the medication begin to work (p=0.02) compared to patients receiving fluticasone/salmeterol combination therapy.1 Budesonide/formoterol combination therapy is not indicated for adjustable dosing in the U.S.

These data showed that patients treated with budesonide/formoterol combination therapy fixed dose were more satisfied with the timeliness of their symptom relief than those patients treated with fluticasone/salmeterol combination therapy, said lead investigator Richard OConnor, MD, of the University of California-San Diego.


'/>"/>

Contact: Katie Neff
katie.neff@astrazeneca.com
302-885-9960
Edelman Public Relations
Source:Eurekalert

Page: 1

Related medicine news :

1. COPD patients benefit more from pulmonary rehab in earlier stages
2. New treatment gives hope for pulmonary fibrosis patients
3. Monitoring whether patients take medicines can help anticipate HIV treatment failure in Africa
4. Medication may prevent depression in patients with head and neck cancer
5. Study: Patients 75 years and older with brain tumors may benefit from more aggressive treatment
6. Bypass not to blame for heart patients mental decline
7. Long-term cognitive decline in bypass patients not due to surgery
8. Clear racial discrepancies exist among patients with CKD
9. Drug brings relief for many IBS patients who experience constipation
10. Depression, PTSD Common Among Lung Transplant Patient Caregivers
11. Depression and PTSD symptoms in caregivers of lung transplant patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... 06, 2016 , ... US Sports Camps has collaborated with State Rugby Organization ... University this summer. Employing world-class rugby figures, including former Team USA players and college ... on key fundamentals, match play, fitness and more. , “US Sports Camps is honored ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... fat areas around the body, is the most popular among body sculpting options, ... make perfect sense to cosmetic surgeon Dr. Richard Buckley, medical director of MilfordMD ...
(Date:5/6/2016)... ... May 06, 2016 , ... From the Speaker Podium to the Exhibit Floor ... its insights on managing Customers Engagement at SpeechTek 2016 Event, taking place May 23-25 ... deliver a Presentation on “5 Customer Engagement Strategies to improve Customer Satisfaction ...
(Date:5/6/2016)... ... 2016 , ... Multiple award winning plumbing company in San Diego, ... Maintaining core values of exceptional customer service, quality work at reasonable rates, and giving ... in San Diego plumbing, and other services including heating & air conditioning and restoration ...
(Date:5/6/2016)... , ... May 06, 2016 , ... This Mother’s Day ... women everywhere. The 17th annual National Women’s Health Week takes place May ... Women’s Health are combining forces to empower women to make their health a top ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... -- , First quarter 2016 adjusted diluted ... million , First quarter reported diluted (GAAP) ... , Company revises 2016 financial guidance; now expects 2016 ... 2016 adjusted diluted non-GAAP earnings per share to range from ... regarding Generics business and manufacturing facility restructuring , ...
(Date:5/5/2016)... , May 5, 2016 Research and ... Imaging in Top 5 EU Markets"  report to their offering.  ... report provides information on the current Positron Emission Tomography (PET) ... Markets (T5 EU), which includes France , ... Spain and the United ...
(Date:5/5/2016)... 2016 Research and ... Systemic Lupus Erythematosus Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Systemic Lupus Erythematosus Market and Competitive Landscape ... Systemic Lupus Erythematosus pipeline products, Systemic Lupus ...
Breaking Medicine Technology: